(Q40558439)

English

Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group

scientific article published on June 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

21 September 2017

Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group (English)

1 reference

Europe PubMed Central

21 September 2017

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

Eastern Cooperative Oncology Group

8

object named as

Eastern Cooperative Oncology Group

1 reference

Europe PubMed Central

21 September 2017

7

object named as

George Wilding

1 reference

Europe PubMed Central

21 September 2017

author name string

Robert Dreicer

1

1 reference

Europe PubMed Central

21 September 2017

Judith Manola

2

1 reference

Europe PubMed Central

21 September 2017

Daniel J Schneider

3

1 reference

Europe PubMed Central

21 September 2017

John F Schwerkoske

4

1 reference

Europe PubMed Central

21 September 2017

Christopher S George

5

1 reference

Europe PubMed Central

21 September 2017

Bruce J Roth

6

1 reference

Europe PubMed Central

21 September 2017

language of work or name

0 references

publication date

1 June 2003

1 reference

Europe PubMed Central

21 September 2017

1 reference

Europe PubMed Central

21 September 2017

97

1 reference

Europe PubMed Central

21 September 2017

2743-2747

1 reference

Europe PubMed Central

21 September 2017

11

1 reference

Europe PubMed Central

21 September 2017

Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11413

7 January 2021

based on heuristic

inferred from DOI database lookup

Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11413

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11413

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11413

7 January 2021

based on heuristic

inferred from DOI database lookup

Recent advances in bladder cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11413

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11413

7 January 2021

based on heuristic

inferred from DOI database lookup

Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11413

7 January 2021

based on heuristic

inferred from DOI database lookup

Advanced bladder and urothelial cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11413

7 January 2021

based on heuristic

inferred from DOI database lookup

Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11413

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11413

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11413

7 January 2021

based on heuristic

inferred from DOI database lookup

2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11413

7 January 2021

based on heuristic

inferred from DOI database lookup

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11413

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11413

7 January 2021

based on heuristic

inferred from DOI database lookup

A Phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11413

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11413

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11413

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.11413

1 reference

Europe PubMed Central

21 September 2017

1 reference

Europe PubMed Central

21 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40558439&oldid=1900547948"